Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Public ClinicalTrials.gov record NCT01196936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer survivors.
Study identification
- NCT ID
- NCT01196936
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Interventions
- Tamoxifen Citrate Drug
- Placebo Drug
- Digital mammography Procedure
- immunohistochemistry staining method Other
- pharmacological study Other
- laboratory biomarker analysis Other
- protein expression analysis Genetic
- pharmacogenomic studies Other
- questionnaire administration Other
- Fine needle aspiration Procedure
- Quality of Life Assessment Other
Drug · Procedure · Other + 1 more
Eligibility (public fields only)
- Age range
- 25 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2010 (Type not available)
- Primary completion
- Dec 11, 2018 (Actual)
- Completion
- Dec 11, 2028 (Estimated)
- Last update posted
- Jan 5, 2026
2010 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| City of Hope Medical Center | Duarte | California | 91010 | — |
| University of Colorado, Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan | Ann Arbor | Michigan | 48109-5718 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01196936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01196936 live on ClinicalTrials.gov.